Carfilzomib (PR-171): Workflow Optimization in Proteasome In
2026-04-20
Carfilzomib (PR-171) empowers cancer researchers with reproducible, high-sensitivity proteasome inhibition, enabling precise apoptosis studies and translational advances. This guide translates bench-proven protocols and troubleshooting strategies into actionable steps, emphasizing data-driven assay design and novel combination approaches.
DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe: Te
2026-04-19
DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe provides high-contrast, orange-red labeling of plasma membranes in both live and fixed cells, particularly suited to neuronal tracing and cell migration assays. It should not be used for aqueous protocols or workflows involving harsh permeabilization or organelle-selective staining.
Iron Stress Alters Enterocyte Metabolism and Inflammation
2026-04-18
This study demonstrates how iron deficiency and excess distinctly reprogram enterocyte metabolism and inflammatory responses. Using IPEC-J2 cells, the research details transcriptional and metabolic adaptations to iron stress, providing foundational insights for investigating iron-dependent cellular pathways and their modulation.
Naloxone Hydrochloride: Advancing Opioid Receptor Antagonist
2026-04-17
Naloxone hydrochloride, a high-purity opioid receptor antagonist, enables precise investigations into opioid signaling, neural stem cell proliferation, and addiction biology. APExBIO’s formulation offers reproducibility and workflow flexibility for cutting-edge research in opioid receptor modulation and withdrawal paradigms.
Perphenazine in Research: Novel Immunological and Neuropharm
2026-04-16
Explore the dual role of Perphenazine as a dopamine D2 receptor antagonist in both neuropharmacology and advanced host-directed antibacterial research. This article provides unique, in-depth analysis and actionable guidance for leveraging Perphenazine in complex assay workflows.
Deferiprone in Iron Stress: Metabolic Reprogramming and Adva
2026-04-15
Explore how Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) enables precise metabolic reprogramming via iron chelation, with new insights from enterocyte metabolism research. Discover actionable, protocol-focused guidance for cancer biology and iron stress studies.
Gentamycin Sulfate: Precision Tools for Resistance Dynamics
2026-04-14
Explore how Gentamycin Sulfate empowers bacterial protein synthesis research and advanced analysis of resistance dynamics. Uncover new assay design insights and practical implications for antibiotic resistance studies.
Optimizing Lipid Peroxidation (MDA) Assay Kit for Translatio
2026-04-13
Accelerate oxidative stress and ferroptosis research with the Lipid Peroxidation (MDA) Assay Kit’s dual-mode detection and robust workflow. This guide delivers actionable setup tips, troubleshooting expertise, and research-driven enhancements inspired by the latest discoveries in drug resistance and biomarker innovation.
Synergistic CDK4/6 and BET Inhibition Modulates Wnt/β-cateni
2026-04-12
Gu et al. (2025) demonstrate that combined inhibition of CDK4/6 and BET proteins synergistically suppresses pancreatic tumor growth and epithelial-to-mesenchymal transition (EMT) via regulation of the GSK3β-mediated Wnt/β-catenin pathway. This mechanistic insight supports rational design of combination therapies targeting Wnt signaling in pancreatic ductal adenocarcinoma.
DCPS as a Biomarker Modulating Epithelial Healing in Diabeti
2026-04-12
This study identifies the decapping scavenger enzyme (DCPS) as a critical regulator and biomarker of epithelial cell function in diabetic foot ulcers (DFU), linking m7G methylation to cell proliferation and wound healing. The findings provide a mechanistic basis for targeting DCPS in chronic wound management and suggest methodological strategies for cell cycle analysis.
Gemcitabine: Protocol Enhancements in Cancer & Apoptosis Ass
2026-04-11
Gemcitabine, a potent DNA synthesis inhibitor, is transforming apoptosis and DNA damage response assays by enabling high-sensitivity, reproducible workflows in cancer research. This deep dive details actionable experimental parameters, troubleshooting strategies, and comparative insights that leverage APExBIO's quality and recent literature breakthroughs.
Homoharringtonine: Cytotoxic Alkaloid Workflows in Cancer &
2026-04-11
Homoharringtonine empowers researchers with a dual-action mechanism, delivering precision in both leukemia modeling and rapid SARS-CoV-2 inhibition. This guide translates breakthrough findings into optimized workflows, troubleshooting strategies, and actionable assay enhancements for modern labs.
Deferiprone: Iron Chelating Agent for Cancer and Cellular...
2026-04-10
Deferiprone is a selective iron-chelating agent used to modulate iron-dependent pathways and induce apoptosis in cancer research. Its robust, stable iron binding and rapid cellular uptake empower precise investigation of iron-mediated oxidative stress and signaling. APExBIO's Deferiprone (SKU: B1723) is a validated standard for studies targeting iron metabolism and homeostasis.
Alfuzosin Hydrochloride: Selective α1-Adrenergic Antagoni...
2026-04-09
Alfuzosin Hydrochloride (A5173) is a functionally uro-selective α1-adrenoceptor antagonist used in benign prostatic hyperplasia (BPH) research. It delivers robust inhibition of intraurethral pressure and smooth muscle relaxation with high oral bioavailability and a favorable cardiovascular safety profile. This article details its pharmacodynamics, validated analytical methods, and best practices for experimental workflows.
Deferiprone (SKU B1723): Optimizing Iron-Dependent Assays...
2026-04-08
This scenario-driven article addresses laboratory challenges in cell viability, proliferation, and cytotoxicity assays, demonstrating how Deferiprone (SKU B1723) from APExBIO offers reproducible, data-supported solutions for iron-dependent signaling and oxidative stress modulation. The guide integrates real-world experimental scenarios, quantitative evidence, and workflow enhancements to help biomedical researchers achieve reliable outcomes in cancer and metabolic disease models.
466 records 22/32 page Previous Next First page 上5页 2122232425 下5页 Last page